Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

181. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage Full Text available with Trip Pro

Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage The authors evaluated the effects of acetylsalicylic acid (ASA) usage and transfusion of previously frozen apheresis platelets on postoperative hemorrhage, activities of daily living (ADL) score, and mortality rate in patients with acute hypertensive basal ganglia hemorrhage undergoing craniotomy.This was a prospective, double (...) -blind, parallel, randomized controlled trial in patients with acute hypertensive basal ganglia hemorrhage, who had either not received ASA therapy (control) or received ASA therapy. The patients who received ASA therapy were divided according to the results of a platelet aggregation test into ASA-resistant, ASA-semiresponsive, and ASA-sensitive groups. All patients required an emergency craniotomy for hematoma removal after hospitalization. The patients who were sensitive to ASA were randomized

2013 EvidenceUpdates Controlled trial quality: uncertain

182. WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism

WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism 1 WARFarin and AcetylSalicylic Acid Study BOTTOM LINE • In patients whom have had a first unprovoked VTE with low to moderate bleed risk, the addition of ASA 100 mg daily is reasonable to prevent future DVT not PE or mortality events, if the decision is made to stop VKA (...) ° outcome of arterial event ?Method for diagnosis of recurrent DVT venous compression ultrasonography has a false positive rate of 14% which may have accounted for observed difference ?Slow recruitment of patients took 6 years to complete ?Small very specific sample size UNCERTAINITIES: ?Applicability to non-caucasian individuals ?2012 Chest guidelines suggest VKA therapy for 3 months but minimum in this study was 6 months 2 k =male,2°=Secondary, ARR=Absolute risk reduction, ASA=Acetylsalicylic Acid

2013 RxFiles

183. ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism

°=Secondary, ARR=Absolute risk reduction, ASA=Acetylsalicylic Acid, CHD=Coronary heart disease, CVD=Cerebrovascular disease, CV= Cardiovascular,CI=Confidence interval, DVT=Deep vein thrombosis, HR= Harm Ratio,GI=Gastrointestinal, HRT=Hormone replacement therapy, ITT=Intention to treat,INR=International normalized ratio, MI=Myocardial Infarction, NR=Not reported, NS=Non-significant, NNT=Number needed to treat,NNH=Number needed to harm, NSAID= Non-steroidal anti-inflammatory drug, PE=Pulmonary embolism, PUD (...) ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 ASPIRE: Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism 1 Aspirin to Prevent Recurrent Venous Thromboembolism BOTTOM LINE • In patients whom have had an unprovoked VTE with low to moderate bleed risk the addition of ASA 100 mg daily is reasonable to prevent future VTE events and major vascular events if the decision is made

2013 RxFiles

184. Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality

Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prophylaxis in people without prior cardiovascular disease does

2013 Evidence-Based Medicine

185. Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes

Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar

2013 Evidence-Based Medicine

186. Cohort study: Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding

Cohort study: Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people

2013 Evidence-Based Nursing

187. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine

188. Ischaemic stroke: sometimes thrombolysis and very often aspirin

Ischaemic stroke: sometimes thrombolysis and very often aspirin Prescrire IN ENGLISH - Spotlight ''Ischaemic stroke: sometimes thrombolysis and very often aspirin '', 1 November 2013 {1} {1} {1} | | > > > Ischaemic stroke: sometimes thrombolysis and very often aspirin Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Ischaemic stroke: sometimes (...) thrombolysis and very often aspirin In the acute phase of an ischaemic stroke, some patients benefit from thrombolysis when it is administered within 3 hours. Most patients are treated with aspirin. Some 80% of strokes are of ischaemic origin (blocked vessels). Around 12% of patients die within the three months following the stroke, and 20% remain in an institution or are highly dependent. When a person shows symptoms of a stroke, it is advisable to get them to hospital as quickly as possible so they can

2013 Prescrire

189. Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding

anti-platelet effect of aspirin in combination with vitamin E. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Celestini/2002 Healthy Human (blood) taking no medication. In vitro study Key results The anti-platelet aggregation effect of acetylsalicylic acid was enhanced in presence of vitamin E, by increasing the NO(nitrous oxide) production 42 fold(P #2) Gonzalez-Correa/2005 Whole blood from healthy (...) Surgery) (Periodontics) (Dental Hygiene) Keywords Vitamin E, Acetylsalicylic acid, collagen, antiplatelet aggregation ID# 2440 Date of submission: 04/01/2013 E-mail Heydaris3@livemail.uthscsa.edu Author Soulmaz Heydari Co-author(s) Co-author(s) e-mail Faculty mentor/Co-author Gregory Spackman, DDS, MBA Faculty mentor/Co-author e-mail spackman@uthscsa.edu Basic Science Rationale (Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent

2013 UTHSCSA Dental School CAT Library

190. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Full Text available with Trip Pro

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone.In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke (...) or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. Treatment

2013 NEJM Controlled trial quality: predicted high

191. Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Full Text available with Trip Pro

Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin given for up to 2 years

2013 Evidence-Based Nursing

192. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis (Abstract)

First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis To perform a systematic literature review as a basis for the update of the Assessment in SpondyloArthritis International Society and European League Against Reumatism (ASAS/EULAR) recommendations for the management of AS with non-pharmacological (...) including coxibs improve BASDAI, disease activity and BASFI. No effect of SSZ and MTX on any variable was found. Surgical interventions of the spine and the hip can give excellent results by restoring function.This concise summary of current evidence for non-pharmacological interventions and non-biologic drugs formed the basis for the update of the ASAS/EULAR recommendations for the management of AS.

2013 EvidenceUpdates

193. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. (Abstract)

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel (...) plus aspirin.We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938.573 patients were

2013 Lancet Controlled trial quality: predicted high

194. Long-term Use of Aspirin and Age-Related Macular Degeneration. Full Text available with Trip Pro

Long-term Use of Aspirin and Age-Related Macular Degeneration. Aspirin is widely used for relief of pain and for cardioprotective effects. Its use is of concern to ophthalmologists when ocular surgery is being considered and also in the presence of age-related macular degeneration (AMD).To examine the association of regular aspirin use with incidence of AMD.The Beaver Dam Eye Study, a longitudinal population-based study of age-related eye diseases conducted in Wisconsin. Examinations were (...) performed every 5 years over a 20-year period (1988-1990 through 2008-2010). Study participants (N = 4926) were aged 43 to 86 years at the baseline examination. At subsequent examinations, participants were asked if they had regularly used aspirin at least twice a week for more than 3 months.Incidence of early AMD, late AMD, and 2 subtypes of late AMD (neovascular AMD and pure geographic atrophy), assessed in retinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.The mean

2012 JAMA

195. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. (Abstract)

Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. 23247951 2013 04 12 2012 12 18 1539-3704 157 12 2012 Dec 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. JC6-2 10.7326/0003-4819-157-12-201212180-02002 Manchak Mike M University of Rochester Medical Center, Rochester, New York, USA. Holloway Robert R eng Comment Journal

2012 Annals of Internal Medicine

196. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials (Abstract)

Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials To study the effect of aspirin in the prevention of pre-eclampsia in high-risk women.Randomised, double-blinded, placebo-controlled trial.Maternity clinics in ten Finnish hospitals participating in the PREDO Project.A total of 152 women with risk factors for pre-eclampsia and abnormal uterine artery Doppler velocimetry.Participants were randomised (...) to start either aspirin 100 mg/day or placebo at 12 + 0 to 13 + 6 weeks + days of gestation. Because of the limited power of this trial, we also conducted a meta-analysis of randomised controlled trials that included data on 346 women with abnormal uterine artery Doppler flow velocimetry, and aspirin 50-150 mg/day started at or before 16( ) weeks of gestation.Pre-eclampsia, gestational hypertension and birthweight standard deviation (SD) score. Outcome measures for the meta-analysis were pre-eclampsia

2012 EvidenceUpdates Controlled trial quality: predicted high

197. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study (Abstract)

Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study To determine the individual variability in the response to aspirin and/or clopidogrel and its impact on graft patency after off-pump coronary artery bypass grafting.A single-centre prospective randomised controlled study designed according to the Consolidated Standards (...) of Reporting Trials statement. Randomisation was obtained by a computer-generated algorithm.University medical school in Italy.300 patients who underwent off-pump coronary artery bypass grafting were randomised to receive aspirin (n=150) or aspirin plus clopidogrel (n=150).Aspirin 100 mg or aspirin 100 mg plus clopidogrel 75 mg daily was initiated when postoperative chest tube drainage was ≤ 50 ml/h for 2 h and patients were followed up for 12 months.Qualitative and quantitative assessment of platelet

2012 EvidenceUpdates Controlled trial quality: uncertain

198. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature

Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

199. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials

Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

200. Aspirin use and breast cancer risk: a meta-analysis

Aspirin use and breast cancer risk: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.